Please assess the completion status of the following clinical trial:

Trial Title: APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent and ability to comply with protocol requirements.~2. Documented diagnosis of AML according to World Health Organization WHO) classification~3. Adequate organ function as defined by the following laboratory values:~   1. Creatinine clearance \> 30 mL/min~  2. Total serum bilirubin \< 1.5 × ULN~  3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 3 × ULN~4. Age ≥18 years~5. At least one TP53 mutation~6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~7. Projected life expectancy of ≥ 12 weeks.~8. Negative serum or urine pregnancy test~9. Females of childbearing potential and males with female partners of childbearing potential must be willing to use an effective form of contraception~Exclusion Criteria:~1. Prior treatment for TP53-mutant AML (\*dependent upon treatment arm assigned).~2. Known history of HIV or active hepatitis B or active hepatitis C infection.~3. Any of the following cardiac abnormalities:~   1. Myocardial infarction within six months prior to registration;~  2. New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction (LVEF) \< 40%;~  3. A history of familial long QT syndrome;~  4. Symptomatic atrial or ventricular arrhythmias~  5. QTcF ≥ 470 msec, unless due to underlying bundle branch block and/or pacemaker and with approval of the medical monitor.~4. Concomitant malignancies for which patients are receiving active therapy~5. Known active CNS involvement from AML.~6. Malabsorption syndrome~7. Pregnancy or lactation.~8. Active uncontrolled systemic infection (viral, bacterial or fungal).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APR-246 (Type: EXPERIMENTAL): APR-246 4.5 g/day

Based on this trial design, predict the completion outcome and termination type (if applicable).